New Tests Delivering Instant, Simultaneous Results for Syphilis, HIV,
and Hepatitis C in Three Distinct Combinations to Debut at 2014 AACC
HALIFAX, July 16, 2014 /CNW/ - MedMira, Inc. (MedMira) (TSXV: MIR) is
expanding its Multiplo product line with the addition of three new multiplex tests that
deliver instant, simultaneous, single-cartridge results for syphilis
(TP), HIV, and hepatitis C. The new tests being added to the product
range include Multiplo TP/nTP, which detects both active and historic
syphilis infections, Multiplo TP/HIV/nTP, and Multiplo TP/HIV/HCV,
which simultaneously detects syphilis, HIV and hepatitis C.
The full Multiplo line is now available in international markets with
analysis of highly regulated markets, possibly including North America
and Europe, underway. MedMira will showcase its full Multiplo line for
the first time at the 2014 American Association for Clinical Chemistry
(AACC) Annual Meeting & Clinical Lab Expo.
The new tests all deliver instant results for syphilis infection, a
disease with an increasing global prevalence rate. Multiplo TP/nTP and
Multiplo TP/HIV/nTP take testing a step further, providing
comprehensive screening and confirmatory results for both present and
past syphilis infections. Detecting the presence of both current and
previous infections provides critical information to help healthcare
providers in determining the right course of treatment for their
"The creativity and innovation powered by our patented RVF Technology is
limitless and this expansion of our Multiplo product range is a prime
example of how the technology enables new rapid tests to fast track
through discovery, design, and development to meet customer demands,"
said Dr. Kevin Jones, Senior Director Sales & Marketing, MedMira. "The
WHO has identified syphilis as a serious global healthcare issue and
our Multiplo tests will prove invaluable in large scale testing
programs targeting multiple diseases, especially prenatal maternal
initiatives. Multiplo TP/HIV is currently under evaluation as part of
the WHO prequalification program and we look forward to working with
them to bring our newest Multiplo tests to screening programs around
The World Health Organization (WHO) estimates that there are more than
12 million new cases of adult syphilis each year, with an additional
500,000 cases affecting infants through maternal transmission. It is
the mission of WHO, and many other healthcare initiatives, to decrease
transmission of HIV and syphilis from mothers to their children. With
prenatal diagnosis using Multiplo rapid tests, at risk pregnancies can
be identified within two minutes, greatly reducing the risk of
mother-to-child HIV and syphilis transmission.
MedMira at AACC
MedMira will debut its expanded Multiplo product line at booth #2143
during the AACC taking place in Chicago from July 29-31. The Company
will also showcase its Multiplo TP/HIV and Multiplo HBc/HIV/HCV tests,
which are slated for launch in the U.S. in 2015, as well as its Reveal® single marker rapid HIV test and Miriad™ research tools.
MedMira also invites conference attendees to join them for the following
OEM Lecture Series - MedMira Rapid Vertical Flow Technology: An in-depth look at how RVF
Technology works and how it can be used to produce multiplexed assays
Dr. Kevin Jones, Senior Director of Sales & Marketing
Wednesday, July 30, 2014, 11:30 am - 11:50 am
"A Rapid and Effective Tool for Monitoring Monoclonal Antibody
Poster # A-325
Tuesday, July 29, 2014, 9:30 am - 5:00 pm
MedMira is a leading developer and manufacturer of vertical flow rapid
diagnostics. The Company's tests provide hospitals, labs, clinics and
individuals with instant diagnosis for diseases such as HIV and
hepatitis C in just three easy steps. The Company's tests are sold
under the Reveal®, Multiplo™ and Miriad™ brands in global markets.
Based on its patented Rapid Vertical Flow Technology™, MedMira's rapid
HIV test is the first one in the world to achieve regulatory approvals
in Canada, the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in Halifax,
Nova Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
approval and launch of new products, future growth, and new business
opportunities. Actual events could materially differ from those
projected herein and depend on a number of factors including, but not
limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MedMira Inc.
For further information:
Andrea Young, Corporate Communications
Chempetitive Group for MedMira:
T. 781-775-3640 E.